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Abstract
Ipilimumab is a fully human, monoclonal antibody directed against Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) that
has demonstrated a survival benefit and durable disease control in patients with advanced melanoma. Ipilimumab
is associated with potentially serious immune-related adverse events, including autoimmune hepatitis. Because
clinical trials of ipilimumab excluded patients with pre-existing hepatitis B or C infection, there is a paucity of data
on the safety of ipilimumab administration to that patient population. Here, we report the largest case series to date
of patients with hepatitis B or C who received ipilimumab for advanced melanoma. Two of the nine patients
described in this case series experienced fluctuations in their liver function tests (LFTs) and were subsequently
treated with corticosteroids. Although this is a small series, the rate of hepatotoxicity appears similar to what has
been seen in the general population treated with ipilimumab, and the ability to administer ipilimumab did not
appear to be affected by concomitant hepatitis B or C infection. The use of ipilimumab in patients with metastatic
melanoma who have pre-existing hepatitis can be considered among other therapeutic options.
Keywords: Ipilimumab, Melanoma, Hepatitis B, Hepatitis C
Background
The US Food and Drug Administration’s approval of ipi-
limumab (Yervoy, Bristol-Myers Squibb, Princeton, NJ)
in 2011 heralded a new era in the treatment of advanced
melanoma. A fully human monoclonal antibody against
Cytotoxic T Lymphocyte Antigen-4 (CTLA-4), ipilimu-
mab demonstrated a survival benefit and durable disease
control in randomized, controlled phase III clinical trials
[1-3]. However, those trials and others performed during
the pre-marketing drug development of ipilimumab ex-
cluded patients with pre-existing hepatitis B or C. More-
over, ipilimumab administration is associated with serious
(grade 3/4) adverse events with potential immune-
related causality, including autoimmune hepatitis.
Although the risk of reactivation of hepatitis B (HBV)
or C (HCV) in infected patients is well-described in pa-
tients receiving cytotoxic chemotherapy [4,5], there is a
paucity of data on the safety of administering ipilimu-
mab or other immunotherapies to that patient popula-
tion [6,7]. Here, we report the largest case series to date
of patients with hepatitis B or C who received ipilimu-
mab for advanced melanoma. All patients received ipili-
mumab at the FDA-approved dose of 3 milligrams per
kilogram of body weight. Cases are described in detail
below and are summarized in Table 1.
Case presentations
Case 1: A 65-year-old man presented with metastatic mel-
anoma involving his lungs and mediastinal and neck lymph
nodes; he had no detectable hepatic metastases. The pa-
tient had contracted HCV (genotype 1a) approximately
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Case
No.
Age
(yrs)
Sex Liver metastases? Type of
Hepatitis
Evidence of
liver fibrosis?
Therapy for
metastatic
melanoma prior to
ipilimumab
LFTs prior to
administration
of ipilimumab
Change in
LFTs
during
Ipilimumab
Best
Response
to Ipi
Comments
1 65 M N HCV
(active)
Y High dose
Interleukin-2
Gr 1 AST, Gr 1
ALT
None PD HCV viral load increased
four-fold after IL-2,
ipilimumab and
temozolomide
2 56 M N HCV
(active)
Unknown Stereotactic
Radiotherapy, then
WBRT
AST & ALT WNL None PD Possible drug-related
hepatitis detected 2 months
after receiving 4 doses of
ipilimumab
3 43 M N HCV
(active)
N Temozolomide Gr 2 AST, Gr 2
ALT
Normalized
by cycle 4
Mixed
response
HCV viral load decreased to undetectable
levels after 4 doses of ipilimumab
4 71 M N HCV
(active)
Y None Gr 1 AST, Gr 1
ALT
Gr 2 AST, Gr
3 ALT after
cycle 3
SD HCV viral load decreased
5-fold to 408,000 IU/mL after
3 doses of ipilimumab;
ocular melanoma
5 56 M (multiple tumors involving 25-75%
of liver, largest= 6.4 cm)
HBV
(inactive)
Unknown None Gr 1 AST, ALT
WNL
None PD Concurrent administration
of entecovir for prophylaxis
against HBV reactivation
6 60 M N HBV
(active)
Unknown high-dose
interleukin-2, talimo-
gene laherparepvec
and dacarbazine
AST & ALT WNL None PD Tenofovir administration prior to ipi
brought HBV viral load from 2950 to 41 IU/mL;
became undetectable and remained so
throughout ipilimumab
7 42 F (multiple tumors involving 30-40%
of liver, largest= 2.7 cm)
HBV
(inactive)
Unknown None AST & ALT WNL None PD HBV viral load undetectable prior to starting
ipilimumab
8 56 M N HBV
(active)
Unknown None AST & ALT WNL None PD Entecavir administration prior to ipi brought
HBV viral load from 9560 to 454 IU/mL;
became undetectable and remained so
throughout ipilimumab
9 71 M N HBV
(active)
Cirrhosis noted
on CT; no
confirming
path findings
None Gr 1 AST, ALT
WNL
None SD HBV viral load 700 IU/mL prior to starting
ipilimumab
Table 1 (Gr, Grade of toxicity as measured by Common Terminology Criteria for Adverse Events (CTCAE) version 4.0; AST, aspartate aminotransferase; ALT, Alanine aminotransferase; LFT, Liver function tests; PD,
Progressive disease; Ipi, ipilimumab; SD, Stable disease)).
R
a
v
i
e
t
a
l
.
J
o
u
r
n
a
l
f
o
r
I
m
m
u
n
o
T
h
e
r
a
p
y
o
f
C
a
n
c
e
r
2
0
1
4
,
2
:
3
3
P
a
g
e
2
o
f
8
h
t
t
p
:
/
/
w
w
w
.
i
m
m
u
n
o
t
h
e
r
a
p
y
o
f
c
a
n
c
e
r
.
o
r
g
/
c
o
n
t
e
n
t
/
2
/
1
/
3
3twenty five years prior to his melanoma diagnosis, though
his hepatitis was never treated. A liver biopsy performed in
2000 demonstrated periportal fibrosis without bridging as
well as mild inflammatory activity. Pathologic findings
from a repeat liver biopsy in 2005 were unchanged. His
melanoma was initially treated with high-dose interleukin-
2 (IL-2) in May 2011. After two cycles, his melanoma had
regressed, but he developed obstructive jaundice secondary
to cholelithiasis with gallbladder sludge, requiring a laparo-
scopic cholecystectomy. Serologic evaluation around the
time of surgery (August 2011) revealed the following: HCV
viral load: 690,000 IU/mL, hepatitis A IgM negative, HBV
core (HBc) IgG and IgM negative, hepatitis B surface anti-
gen (HBsAg) negative. A liver biopsy performed during
surgery revealed cirrhosis with mild, non-specific inflam-
mation and focal hemosiderin accumulation. He received
two more cycles of IL-2, but his melanoma subsequently
progressed and he began treatment with ipilimumab in
November 2011. During and after ipilimumab administra-
tion, hepatic transaminases remained unchanged from
baseline, with grade 1 elevations. Although the patient tol-
erated 4 cycles of ipilimumab without drug-limiting toxic-
ities, he experienced disease progression and was
transitioned to temozolomide. After three cycles of temozo-
lomide, HCV viral load had increased four-fold to
2,720,000 IU/mL. The patient expired sixteen months after
the initiation of ipilimumab from progression of his
melanoma.
Case 2: A 56-year-old man with HCV was found to
have stage IIIA cutaneous melanoma. A local recurrence
in June 2010 was treated with excision and axillary
lymph node dissection. Laboratory values at that time
revealed an aspartate aminotransferase (AST) of 45 IU/L
(normal range 0-40 IU/L), a normal alanine aminotrans-
ferase (ALT) (0-55 IU/L), a negative HBsAg, a negative
HBc IgM, a positive HCV antibody and an HCV viral
load of 103,160 IU/mL. He did not receive systemic
treatment for his hepatitis. Subsequent restaging scans
demonstrated new metastases in lymph nodes, muscle
and brain. He underwent stereotactic radiosurgery for
his brain lesion followed by two cycles of temozolomide.
During systemic therapy with temozolomide, the pa-
tient’s hepatic transaminases rose: AST 254 IU/L, ALT
325 IU/L. Shortly thereafter, new brain and soft tissue le-
sions appeared. Whole-brain radiotherapy was adminis-
tered, followed by initiation of ipilimumab in April 2011.
Immediately prior to ipilimumab administration, hepatic
transaminases had normalized (AST 29 IU/L, ALT
17 IU/L), and HCV viral load was 3,070 IU/mL. He
underwent four cycles of ipilimumab without significant
changes in liver function tests. The patient experienced
progressive disease five months after initiating ipilimu-
mab, at which time HCV viral load was 2,279,050 IU/mL,
and AST and ALT had increased to 208 and 119 IU/L,
respectively. Because of the potential for immune-related
causality, corticosteroid therapy was administered, with
improvement of hepatic transaminases (AST 117, ALT
36 IU/L). The patient then enrolled in a phase I clinical
trial of a pan-RAF kinase inhibitor due to progression of
disease, and was maintained on steroids during the course
of experimental therapy. His course was marked by liver
function test fluctuations (AST 35-117, ALT 28-132 IU/L)
as well as adrenal insufficiency after decreasing the pa-
tient’s dose of corticosteroids. Ten months after initiating
ipilimumab, HCV viral load was >69,000,000 IU/mL, how-
ever, his hepatic transaminase levels subsequently normal-
ized. Although his viral load and LFTs were discordant,
the patient was approaching hospice care at this time and
further investigation of the significance of these findings
was postponed. Two months later, the patient died from
progressive melanoma. Of note, this case was previously
reported in detail but summarized here to augment the
current case series [7].
Case 3: A 43-year-old man presented with metastatic
melanoma involving axillary, hilar and pericardiac lymph
nodes and soft tissue adjacent to the umbilicus, but no
hepatic lesions. He was treated with six cycles of temo-
zolomide, during which liver transaminases became ele-
vated: AST 85 IU/L (normal 8-48 IU/L), ALT 164 IU/L
(10-40 IU/L). The transaminitis persisted after discon-
tinuation of temozolomide. An abdominal computed
tomography (CT) scan showed no evidence of intra-
abdominal metastases or hepatic cirrhosis; however se-
rologies revealed HCV with a viral load of 398,938 IU/
mL, genotype 1a. The patient tolerated four cycles of ipi-
limumab from April 2012 to July 2012 without interrup-
tion or complication. He had a mixed response to
ipilimumab, but never progressed. Hepatic transami-
nases normalized by cycle 4, and HCV viral load was de-
tectable at <12 IU/mL approximately four weeks later.
Post-therapy the patient’s viral load began to climb:
1,378 IU/mL at eight weeks and 1,558 IU/mL at four-
teen weeks after the fourth cycle of ipilimumab was ad-
ministered. A remaining melanoma lesion in the right
hilum was irradiated, and subsequent imaging with posi-
tron emission tomography (PET)/CT in January 2014
and CT in July 2014 demonstrated no evidence of dis-
ease. Since completing ipilimumab, HCV viral load has
remained stable with normal LFTs. Of note, this case
was previously reported in detail but summarized here
to expand the current case series [6].
Case 4: A 71-year-old man presented with metastatic
ocular (choroidal) melanoma without hepatic involve-
ment. His primary lesion had been treated thirteen years
earlier with right orbital enucleation. Three years after
enucleation he was diagnosed with HCV but did not re-
quire treatment. Evaluations for hepatitis A, HBV and
HIV were negative. Serologic evaluation prior to initiation
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mL and grade 1 AST and ALT. Three weeks after one
cycle of ipilimumab, the patient was found to have grade 2
and 3 elevations of ASTand ALT, respectively. Ipilimumab
was held and high-dose prednisone was administered.
HCV viral load had decreased to 408,000 IU/mL. Liver bi-
opsy demonstrated chronic, active Scheuer grade 2 hepa-
titis and Scheuer stage 2 periportal fibrosis. There was no
evidence of associated autoimmunity; a panel of serologic
markers associated with autoimmune hepatitis (anti-nu-
clear cytoplasmic antibody, IgG; double stranded DNA
antibody, IgG; F-actin antibody, IgG; anti-soluble liver
antigen, IgG; mitochondrial M2 antibody, IgG; liver kid-
ney microsome antibody; and anti-neuronal nuclear anti-
body) was negative. Extractable nuclear antigen screen
was equivocal and was not pursued. His serum IgG was
mildly elevated at 1630 mg/dL (normal range 694-1,618).
As there was no evidence of autoimmune hepatitis, his
prednisone was discontinued. Magnetic resonance imagin-
ing (MRI) of the abdomen revealed no evidence of malig-
nancy. The patient’s ALT and AST returned to grade 1,
and, after a brief dose delay, ipilimumab was restarted
with subsequent normalization of hepatic transaminases.
Five months after initiation of ipilimumab the patient’s
melanoma was stable and HCV viral load was 108,000 IU/
mL. Eight months after initiation of ipilimumab, however,
a bronchoscopy and PET/CT scan both showed progres-
sion of disease without hepatic involvement. Shortly there-
after, serum AST and ALT became elevated (grade 1).
HCV viral load measured 11 months after initiation of ipi-
limumab increased to 653,000 IU/mL. The patient was
treated with temozolomide, which was discontinued due
to thrombocytopenia. He subsequently relocated and was
lost to follow-up.
Case 5: A 56-year-old man with a history of HBV pre-
sented with stage IV melanoma involving the liver (mul-
tiple tumors, largest =6.4 cm), pancreas, kidney, bones
and mediastinal lymph nodes. At the time of ipilimumab
administration, the patient’s serum AST was 61 IU/L
(normal range =8-48) and ALT was normal at 25 IU/L.
His bilirubin was mildly elevated at 1.57 mg/dL (0.1-1.2).
Serologies revealed the following: HBsAg negative; HBV
DNA undetectable by polymerase chain reaction (PCR);
HBc reactive; HBV surface antibody negative, suggesting
an inactive carrier state. The patient did not have a liver
biopsy, so it is unclear if he had fibrosis at the time of
ipilimumab administration. The patient completed a
total of 3 cycles of ipilimumab, along with concurrent
administration of entecavir for prophylaxis against HBV
reactivation. Though his liver function tests remained
normal throughout therapy, the final cycle of ipilimumab
was withheld due to clinical decompensation consisting
of progressive fatigue and pain due to bone and liver
metastases. The patient died of progressive melanoma
shortly after receiving his third cycle of ipilimumab ther-
apy, at which time hepatic transaminases were within
normal limits.
Case 6: A 60-year-old man presented with stage IV
melanoma including multiple subcutaneous metastases.
He had previously undergone adjuvant therapy with
interferon alfa (IFNα) after surgical resection of his pri-
mary lesion, as well as radiation therapy after resection
of a local recurrence. Prior therapies for metastatic dis-
ease included high-dose IL-2, talimogene laherparepvec
and dacarbazine with disease progression after each.
Two months prior to the initiation of ipilimumab, the
patient’s serum AST and ALT were within normal limits
with a reactive Hepatitis B e-Antibody (anti-HBe), non-
reactive Hepatitis B e-Antigen (HBeAg), and HBV viral
load of 43,100 IU/mL. Without intervening therapy,
HBV viral load fell to 2,950 IU/mL ten days later. Teno-
fovir therapy was initiated. After four days of treatment
the patient’s viral load was 41 IU/mL. Four cycles of ipi-
limumab were administered, which were well-tolerated
and produced no LFT abnormalities. One month later,
HBV viral load was undetectable. The patient expired
four months after initiation of ipilimumab from progres-
sive melanoma. Of note, this case was previously re-
ported in detail but summarized here to expand the
current case series [7].
Case 7: A 42-year-old Vietnamese woman, who had
undergone resection of a mucosal (anal) melanoma two
years earlier, presented with metastatic melanoma in-
volving liver and bone. Serologies prior to treatment
with ipilimumab revealed an undetectable HBV DNA by
PCR, a negative HBeAg and positive anti-HBe, indicating
viral exposure and clearance. Liver function studies were
within normal limits prior to initiation of ipilimumab
and remained normal throughout all 4 cycles of therapy.
Though the patient did not experience any ipilimumab-
related toxicity, radiologic scans performed one month
after the final cycle demonstrated progression of disease.
Case 8: A 56-year-old Venezuelan man with HBV, who
had previously received adjuvant IFNα after resection of
a primary melanoma (cKIT mutant), presented with
metastatic disease including pancreatic and splenic me-
tastases. Prior to the initiation of ipilimumab, the pa-
tient’s HBV DNA level was 9560 IU/mL with normal
liver function tests. The patient stated that he had a liver
biopsy in South America which was within normal
limits; however this was not confirmed by repeat liver
biopsy, although his radiographic imaging from the US
does not show evidence of fibrosis. The patient was ad-
ministered entecavir 0.5 mg daily, after which the viral
load fell to 454 IU/mL. Ipilimumab was initiated 2 weeks
later and entecavir was continued. The patient’s viral load
became undetectable, and his LFTs remained within nor-
mal limits throughout the course of treatment. Although
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complications, post-therapy radiologic scans demon-
strated progressive disease. He was subsequently treated
with temozolomide, then nilotinib, again without hepatic
complications.
Case 9: A 71-year-old man presented with stage IV
melanoma. He had received adjuvant IFNα after his ini-
tial melanoma diagnosis and surgical resection seven
years prior, which coincided with a diagnosis of HBV.
Hepatic transaminases prior to administration of IFNα
were normal, though IFNα was held several times due to
grade 2 and 3 elevations of ALT and AST. Three years
prior to administration of ipilimumab, the patient was
initiated on HBV treatment with tenofovir after serologic
markers revealed a HBV viral load of >200,000,000 IU/
mL and CT imaging demonstrated cirrhotic morphology
and small volume ascites. One year into tenofovir ther-
apy, HBV viral load had decreased to 1900 IU/mL. Two
years later, laboratory evaluation immediately prior to
initiation of ipilimumab revealed normal ALT, grade 1
elevation of ASTand HBV viral load of 700 IU/mL. Hep-
atic transaminases remained stable throughout ipilimu-
mab induction therapy, which resulted in stable disease
for seven months. The patient’s melanoma then pro-
gressed, which was again treated with ipilimumab. ALT
remained normal, AST remained grade 1; however the
patient’s melanoma progressed five months later with no
evidence of hepatic involvement. The patient remains on
tenofovir at the time of this publication.
Conclusions
Although ipilimumab has undergone extensive clinical
testing in patients with melanoma [8], its use in patients
with infectious co-morbidities remains poorly character-
ized. Patients bearing similarity to the population
broadly studied during clinical development often re-
ceive all four cycles of ipilimumab without evidence of
autoimmune toxicity. However, other patients experi-
ence adverse events with potential immune-related caus-
ality, [otherwise “immune-related adverse events”] that
can be dose limiting and cause significant morbidity [9].
Indeed, the two large phase III trials conducted prior to
the drug’s approval by the FDA excluded patients receiving
immunosuppressive medications, those with conditions re-
quiring the long-term use of systemic corticosteroids and
those with acute or chronic viral hepatitis. Since the side
effect profile observed with ipilimumab differs significantly
from that of standard cytotoxic chemotherapy due to its
unique mechanism of action, understanding its relative
safety in patients with hepatitis infection is crucial in help-
ing to establish treatment guidelines. This is especially
important in light of the fact that immune-mediated hep-
atotoxicity, a known adverse effect of ipilimumab, is of par-
ticular concern in patients with concomitant viral hepatitis.
This concern arises from the theoretical risk of hepatitis
B/C reactivation and the potential for immune-mediated
liver damage in patients whose hepatic function may be
compromised at baseline.
Chemotherapy-induced reactivation of hepatitis B or C
that results in significant hepatic decompensation is well
described [4,5]. Higher serum viral load prior to the ini-
tiation of therapy may influence risk of reactivation, and
high pretreatment HBV DNA levels have been shown to
correlate with poor tolerance to cytotoxic chemotherapy
[10,11]. Several of these issues are being investigated in
ongoing clinical trials. (NCT01658878)A theoretical risk
of viral reactivation exists with the use of ipilimumab be-
cause of the presence of CTLA-4 on T regulatory (Treg)
cells. This sub-population of immunoregulatory T cells
suppresses the activation and effector function of CD4+
and CD8+ T cells [12-14]; thus, activating Tregs by block-
ing CTLA-4 may further impair the ability of T cells to
keep viral hepatitis suppressed [15]. On the other hand,
HCV viral replication is associated with “exhausted” CD8+
T cells, which express immune-inhibitory receptors, such
as CTLA-4 and Programmed Death-1 (PD-1) (see Figure 1;
[16]). Blockade of one or more of these immune check-
points has demonstrated a decrease in HCV viral load and
a reversal of HCV-specific T cell exhaustion which may
stimulate an antiviral response [6,17-19]. Indeed, this
phenomenon may underlie the decrease in viral load ob-
served after administration of ipilimumab in case #3, de-
scribed above. A similar mechanism may have led to the
activation and proliferation of tumor-specific T cells, cul-
minating in a durable anti-tumor response.
Autoimmune hepatotoxicity is a side effect of ipilimu-
mab and of immune checkpoint inhibitors as a class. In
a phase III trial combining ipilimumab with dacarbazine
as first-line therapy for advanced melanoma, 78 of 247
(31.6%) patients who received both drugs experienced
grade three or four immune-mediated hepatitis [3]. Of
note, because dacarbazine monotherapy can cause hepato-
toxicity, interpretation of these results was challenging. In
a study of twenty one patients with hepatocellular carcin-
oma and chronic hepatitis C who received tremelimumab,
another CTLA-4 blocking antibody, 45% experienced a
transient grade three or higher rise in liver transaminases
after the first dose [17]. Similarly, evidence of drug-related
hepatic toxicity has also been reported with PD-1 anti-
bodies [20,21]. In lieu of these risks, recommendations for
administration of ipilimumab include monitoring of hep-
atic function tests prior to each dose and the rapid initi-
ation of corticosteroid therapy in patients with≥grade 3
elevations of hepatic transaminases that are unrelated to
melanoma progression [9]. In such patients, some investi-
gators assess levels of serum autoimmune markers such as
anti-nuclear antibodies, anti-smooth muscle antibodies
and anti-nuclear cytoplasmic antibodies. Two of the nine
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chronic HCV infection, experienced fluctuations in LFTS
and were treated with corticosteroids. Although this is a
small series, the rate of hepatotoxicity appears similar to
what was seen in the general population treated with ipili-
mumab, and the ability to administer ipilimumab did not
appear to be affected by concomitant hepatitis B or C
infection.
There remain limited published data describing the
safety of ipilimumab administration to patients with
metastatic melanoma who have pre-existing HBV or
HCV. Although the nine patients described herein (five
with HBV, four with HCV) represent the largest case
series on this topic, our report is limited by the retro-
spective collection of data from all patients. For instance,
viral load information was not available on every patient
treated to allow for uniform comparisons. The use of
ipilimumab in patients with metastatic melanoma who
have pre-existing hepatitis can be considered among other
therapeutic options. Careful attention to baseline hepatic
function and additional comorbidities is critical, as is close
monitoring of LFT trends while patients are receiving
therapy and consultation with specialists in chronic liver
disease. As in patients treated with chemotherapy, patients
with Hepatitis B infection may be candidates for concomi-
tant HBV suppression with antiviral therapies, an add-
itional risk mitigation strategy. Although a concomitant
diagnosis of HBV or HCV is not an absolute contraindica-
tion to the administration of ipilimumab, a more thorough
characterization of the drug’s effect on hepatitis, in par-
ticular viral load suppression, requires further evaluation
in prospective studies.
Consent
Written informed consent was obtained from the patients
for publication of this Case series. A copy of the written
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Figure 1 The process of T cell exhaustion in chronic viral infection and possible effects of ipilimumab. a) After the introduction of initial
antigen (infection), naive CD8+ T cells are primed by antigen and, with concomitant stimulation and ongoing inflammation, mature into effector
CD8+ T cells. As the antigen (infection) clears, a subset of the effector CD8+ T cells further differentiate into memory CD8+ T cells with the ability
to produce cytokines such as IL-2, tumor necrosis factor (TNF) and interferon-γ (IFN-γ), then degranulate, proliferate and self-rejuvenate. In the event of
chronic antigen exposure (infection) and subsequent increasing viral load and persistence of antigen (infection), mature effector CD8+ T cells proceed
through a hierarchical process of exhaustion, loss of effector functions including the ability to produce cytokines and degranulate, the progressive
expression of inhibitory receptors, and the loss of the ability to proliferate and self-rejuvenate and elimination. These processes culminate in thel o s so f
virus-specific CD8+ T cell responses. b) Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) is an inhibitory receptor expressed on the surface of exhausted
CD8+ T cells. It is analogous to, but serves the opposite function of, the CD28 T cell receptor also found on the surface of these cells. Activated antigen
presenting cells (APC) loaded with antigen express CD80/86, which can either bind CD28 resulting in a stimulatory signal, or bind to CTLA-4 resulting
in attenuation of further intracellular signaling and gene expression and ultimately CD8+ T cell response. c) Ipilimumab is a monoclonal antibody that
targets the CTLA-4 receptor on CD8+ T cells. It functions by binding the CTLA-4 receptor, thus preventing CD80/86-CTLA-4 binding and the resultant
CD8+ T cell attenuation, thereby halting and potentially reversing the process of CD8+ T cell exhaustion.
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